Scenesse
afamelanotide · Clinuvel Europe Limited
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Scenesse is used for
Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Scenesse
- Active substance
- afamelanotide
- Disease area
- Protoporphyria, Erythropoietic
- Medicine group
- Emollients and protectives
- ATC code
- D02BB02
- Marketing authorisation holder
- Clinuvel Europe Limited
- Authorised in the EU since
- 2014
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Scenesse used for?
Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
What is the active substance in Scenesse?
Scenesse contains afamelanotide.
Who makes Scenesse?
The EU marketing authorisation holder is Clinuvel Europe Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU